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Abstract 
Chronic pelvic pain is a common condition in men that is defined as 3 months of pain or discomfort 
in the pelvic region associated with urinary symptoms and/or sexual dysfunction. It is a diagnosis of 
exclusion and the aetiology is poorly understood. Hypotheses include increased pelvic floor tone as 
well as infective and inflammatory causes. Given the wide variation in symptoms and potential 
causes, it is important to spend time collating an individual patient’s symptom profile so the 
management plan can be tailored appropriately. A  national multidisciplinary consensus guideline 
recommends a multidisciplinary team approach with pharmacotherapeutic, physical and 
psychosocial components integrated into a holistic treatment programme individualized to the 
patient. Management is likely to include a combination of interventions such as antibiotics, α-
adrenergic antagonists and simple analgesics, alongside pelvic floor relaxation and psychological 
support. Detailed discussion with patients about the feedback loops involved in pelvic muscle 
tension and pelvic pain has also been found to be therapeutically beneficial. 
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Key points 
• Pain can be felt anywhere throughout the pelvis and genitals, and can be associated with 
lower urinary tract symptoms and sexual dysfunction 
• The aetiology of the condition is poorly understood. Hypotheses include increased pelvic 
floor tone and infective and inflammatory causes 
• An individual patient’s symptoms profile can be collated from a careful history and validated 
symptom scores  
• Management can then be tailored to the individual patient’s symptoms and will probably 
include a combination of pharmacological and non-pharmacological interventions 
 
Introduction 
The chronic symptomatic prostatitis syndromes include chronic bacterial prostatitis and chronic 
prostatitis/chronic pelvic pain syndrome (CP/CPPS), the latter being much more common.1,2 
CP/CPPS, on which this article focuses, is defined as pain or discomfort in the pelvic region, 
  
associated with urinary symptoms and/or sexual dysfunction, that has lasted for at least 3 of the 
previous 6 months, and for which differential diagnoses have been excluded. 1,2 
CP/CPPS presents a major healthcare burden in men, with a prevalence of 8.2% (range 2.2–9.7%).1,2  
It can have a significant impact on patients’ quality of life, but its poorly understood aetiology and 
complex pathophysiology pose a challenge to effective management and often lead to 
unsatisfactory treatment outcomes.1–3 Clinical trials have failed to identify an effective 
monotherapy, and current recommendations are largely based on expert opinion. Current guidelines 
advise clinicians to identify the patient’s individual symptom pattern and adopt a symptom-based 
treatment approach that also addresses psychosocial factors. 1–3 
 
Aetiology 
The aetiology of CP/CPPS is not well understood, and the underlying pathophysiology is likely to be 
complex. CP/CPPS is thought to be the result of inflammatory, infectious damage and/or 
neurological dysfunction.2,3 However, infective causes, such as bacterial prostatitis and non-
gonococcal urethritis, appear to account for only a minority of cases.1–3 
Experience from a specialist CP/CPPS clinic in Bristol, supported by the literature, indicates that 
many patients have increased pelvic floor muscle tone. This can cause a symptomatic increase in 
urethral resistance to urinary flow and/or reflux into the prostate.3,4 Because many pelvic organs, 
including the prostate, bladder, urethra, rectum and genital structures, are innervated by the same 
nerve plexus, it is possible that pain from increased pelvic floor muscle tone and/or intraprostatic 
urinary reflux can be experienced as referred pain throughout the pelvis.3,4  
 
Men with obsessive personality traits who tend to get locked into circular trains of thought are over-
represented in patients with CP/CPPS in Bristol.3 These men may subconsciously tense their pelvic 
floor muscles when stressed, which could itself be the cause of pain. Underlying anxiety about the 
cause of pain may worsen symptoms further. This can create a positive feedback loop in susceptible 
men, with anxiety about their CP/CPPS leading to increasing symptoms, which then further increases 
their anxiety (Figure 1).3  
 
  
 
Figure 1  
Adapted from Crofts et al.3 
 
 
Diagnosis 
History  
CP/CPPS can present in a variety of ways. Patients can complain of pain anywhere in the pelvis, most 
commonly lower abdominal, perineal, testicular, penile and/or ejaculatory pain. Pain is often 
accompanied by lower urinary tract symptoms (LUTS) such as dysuria and voiding difficulties, as well 
as sexual dysfunction.1–3  
 
Because CP/CPPS is a diagnosis of exclusion, it is important to ensure that other differential 
diagnoses have been ruled out. This includes testicular and prostatic cancer, urinary tract infection, 
chronic bacterial prostatitis, infectious causes of non-gonococcal urethritis, epididymo-orchitis, 
bladder outlet obstruction, urethral stricture, balanitis xerotica obliterans and inguinal hernia. 
 
Because of the multifactorial nature of the condition, it is important to spend time collating a 
symptom profile, including potential precipitating factors. This can involve  taking a detailed sexual 
  
history and exploring the patient’s psychosocial symptoms (e.g. anxiety, stress) and past medical, 
drug and social history, including details of their support network.2,3 By adopting an ‘active’ listening 
approach, the physician can begin to develop a therapeutic relationship, enabling the patient to 
disclose specific anxieties and concerns they have about the cause and consequences of the pain, for 
example persistent infection, malignancy and infertility.3 Exploring a patient’s personality traits is 
also helpful as, in our experience, patients with a problem-solving persona (obsessive personality 
trait) respond better to a detailed explanation of the probablee aetiology than those who suffer 
from anxiety.  
 
The National Institutes of Health Chronic Prostatitis Symptom Index (NIH – CPSI; Figure 2) is an 
objective assessment tool that can be used to monitor patients’ symptoms; it should be completed 
at each consultation. This score covers the type, frequency and severity of pain and associated 
symptoms, as well has how much these symptoms are impacting on the patient’s quality of life. A 6-
point decline from the baseline total score is considered the threshold for a positive therapeutic 
response, although a 25% decrease can also be used.1,5 
 
  
 
Figure 2 The NIH-CPSI 
Available from http://www.upointmd.com/NIHCPSIEnglish.pdf. 
 
Examination 
This should include: 
• abdominal examination, including hernial orifices 
• genital examination of the penis and testicles 
  
• digital rectal examination (DRE) to assess prostate size, tenderness and pelvic floor muscle 
tone. It is important to differentiate between tenderness felt on palpation of the prostate 
and tenderness associated with palpation of the pelvic floor muscles. Pelvic floor muscle 
tenderness can be assessed by palpating the prostatic bed.  
These examinations can be carried out in non-specialist settings, and can provide useful information 
for excluding other diagnoses and helping to guide individual management. For example, if the 
doctor can demonstrate to the patient that he has increased pelvic muscle tone, with tenderness on 
palpation, and then explain how this could result in symptoms experienced elsewhere in the pelvis 
(referred pain), this can lead to a focus on pelvic floor relaxation exercises within the management 
plan.3,5  
 
Investigation 
A list of potential investigations is detailed in the UK multidisciplinary consensus guideline; they are 
divided into those which can be undertaken in non-specialist and specialist settings.2 These help to 
exclude the differential diagnoses detailed above.  
 
The following are considered to be core investigations: a urinary dipstick and/or midstream urine 
specimen for culture, microscopy and sensitivity to exclude the presence of a urinary tract infection 
and haematuria; a nucleic acid amplification test (NAAT) test for chlamydia (if at risk3); and prostatic-
specific antigen (PSA), if indicated.2 The UK consensus guideline provides advice on when to 
undertake PSA testing.2 In a specialist setting, testing for chronic bacterial prostatitis using the four- 
or two-glass test, and/or for urethritis and other sexually transmitted infections, such as 
Mycoplasma genitalium, can be undertaken in order to exclude these infections.2,3  
 
Other investigations include uroflowmetry, cystoscopy or retrograde urethrography in order to 
exclude bladder outlet obstruction, urethral stricture or bladder neck stenosis in selected patients 
with LUTS.1–3,5 Investigations such as full blood count and inflammatory markers have not been 
shown to be helpful in diagnosis.1  
 
 
 
 
  
Management 
Single treatment modalities have proved largely ineffective in the management of CP/CPPS, perhaps 
not surprisingly considering the likely multifactorial nature of the condition. The expert consensus is 
that patients should be managed according to their individual symptom profile.1,2 
 
The national consensus guideline explores, in detail, the evidence base supporting potential 
therapeutic interventions and advises on how men with CP/CPPS should be managed.2 Options for 
first-line pharmacological treatment include antibiotics, α-adrenergic antagonists and simple 
analgesics. For patients with early-stage chronic bacterial prostatitis and CP/CPPS, a quinolone (e.g. 
ciprofloxacin, ofloxacin) for 4–6 weeks is recommended as first-line therapy. A repeat course of 
antibiotic therapy should be offered only if a bacterial cause is confirmed or there is a partial 
response to the first course of treatment.2 Treatment with α-adrenergic antagonists should be 
considered in patients who present with significant LUTS on voiding.2 There is some evidence that a 
combination of α-adrenergic antagonists and antibiotics may be more effective than monotherapy.1–
3,5 Early use of treatments targeting neuropathic pain and/or referral to specialist services should be 
considered for patients who do not respond to initial measures. 
 
If a clinically relevant level of psychosocial symptoms is observed, referral to a psychosocial specialist 
(e.g. psychiatrist, specialist psychologist, cognitive behavioural therapist) should be considered.2 
Therapies that aim to improve relaxation and coordinated use of the pelvic floor muscles, such as 
biofeedback physical therapy and pelvic floor re-education, as well as myofascial trigger point 
release, can play a role in improving symptoms in patients with CP/CPPS.2  
 
The national consensus guideline recommends a multidisciplinary team (MDT) approach, with 
pharmacotherapy, physical and psychosocial approaches integrated into a holistic treatment 
programme that is individualized to the patient.2 The MDT can include urologists, pain specialists, 
nurse specialists, specialist physiotherapists, general practitioners, cognitive behavioural 
therapists/psychologists and sexual health specialists.2  
 
The specialist CP/CPPS clinic where the authors are based uses a biopsychosocial approach tailored 
to individual patients. This can include a combination of interventions including pharmacological, 
psychological and pelvic floor muscle relaxation advice, including physiotherapy referral.3 Patients 
  
are managed by one clinician who refers patients as necessary if they have a poor response to initial 
interventions.  
 
If increased pelvic floor muscle tone and tenderness is detected on DRE, experience has 
demonstrated that patients benefit from an explanation about the feedback loop of pelvic pain, 
anxiety and increased pelvic tone (see Figure 1).3,5 The authors have found it useful to use a detailed 
patient information leaflet (available on request) containing a diagram of the pelvic floor structures, 
alongside a diagram illustrating this feedback loop. Verbal and written advice on pelvic floor 
relaxation techniques, specifically on how to undertake pelvic floor drop exercises, is provided 
(available on request). Distraction techniques such as mindfulness and physical exercise are also 
promoted. The use of α-adrenergic antagonists is not limited to men with LUTS and is also used in 
men without LUTS who have increased pelvic floor muscle tone on DRE. Men who respond poorly to 
these initial interventions are referred for pelvic floor physiotherapy to teach them how to isolate 
and relax their pelvic floor muscles, and/or a pain specialist.  
 
In men with urethritis, which is non-infective (NAAT-negative for Chlamydia and M. genitalium) and 
possibly linked to intraprostatic urinary reflux, clarithromycin 500 mg twice daily for 3 weeks is 
prescribed. This is an off label use based on a previous study indicating that 3 weeks of erythromycin 
500mgs qds can be of benefit, as clarithromycin is better tolerated.3 This probably works through its 
anti-inflammatory properties.3,5 Patients with bothersome LUTS who do not respond to initial 
therapy are referred for urological assessment.3,5  
 
Despite the definition of CP/CPPS stating that the pain must have been present for 3 of the 
preceding 6 months, it is possible that earlier identification, enabling exploration and discussion of 
the possible underlying mechanisms, with appropriate management and reassurance, could reduce 
overall morbidity by shortening the duration of symptoms.3,5 This is supported by the observations 
of Kenyon et al., who reviewed outcomes for 24 men in Bristol with CP/CPPS symptoms, identified 
early (<90 days’ duration) and late, with an average NIH-CPSI score of 24.7. They observed a similar 
fall in NIH-CPSI score, of 8.5 versus 10.3, respectively.3,5 This, however, needs formal evaluation in a 
clinical trial.  
 
  
Prognosis and follow-up 
In general, patients have a gradual response to treatment and need support and reassurance while 
undergoing management. This can be provided through follow-up in a specialist CP/CPPS service 
using an MDT approach.2,3,5  
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Question 1 
A 29-year-old man presented  with a 1-month history of an uncomfortable sensation at the tip of his 
penis and pain passing urine. He also described the sensation of not being able to completely empty 
his bladder after passing urine. He had had a negative chlamydia and gonorrhoea nucleic acid 
amplification test (NAAT) at his GP 2 weeks previously. Examination of his penis and testicles was 
normal.  
 
What is the most appropriate initial investigation? 
A Testicular ultrasound scan  
B Urine dipstick 
C Urethral smear 
D Chlamydia and gonorrhoea NAAT 
E Prostate-specific antigen 
 
Answer: C.  If a urethral smear is available, it will provide the most accurate and immediate 
information on whether there is urethritis. The patient has no testicular symptoms or signs, so an 
ultrasound scan (A) will not be helpful. Urine dipstick (B) can provide some information to 
distinguish between a urinary tract infection (leucocytes alongside nitrites and blood) and a sexually 
transmitted infection (leucocytes only). However, given that a sexually transmitted infection is the 
most likely cause in a man of this age, a urethral smear will be more sensitive.Chlamydia and 
gonorrhoea nucleic acid amplification testing (D) will be helpful and should be performed in this 
patient. However, he recently tested negative after the onset of his symptoms, so it is very unlikely 
that either of these infections will be causal in this case. Chlamydia only causes about 40% of cases 
of non-gonococcal urethritis. In addition, a urethral smear will provide immediate results to enable a 
diagnosis to be made in clinic. Prostate-specific antigen (E) is not a first-line investigation here as the 
patient is not in the right age cohort. 
 
 
Question 2 
A 32year-old man presented with intermittent pain passing urine and a dull ache felt at his 
perineum. He was also experiencing increased frequency of urination. Two months previously, he 
had been found to have  non-gonococcal urethritis. This initially responded well to  antibiotics, but 
his symptoms had returned shortly after completing treatment. Digital rectal examination showed a  
smooth, normal sized, non-tender prostate.  The prostatic bed (pelvic floor muscles) was tense and 
tender to palpation.  
 
Investigations 
•Early morning urethral smear was negative 
•Mycoplasma genitalium nucleic acid amplification test was negative 
 
 
What is the most important next step in pharmacological management? 
A Paracetamol 
B Ibuprofen 
C Antibiotics for 4 weeks 
D α-Adrenergic antagonists 
E Gabapentin 
 
Correct answer: D. All of these pharmacological interventions can play a role and can be used in 
conjunction with each another. However, α-adrenergic antagonists are the most important as the 
  
patient has lower urinary tract symptoms and evidence of increased pelvic floor tone on digital 
rectal examination.  
 
 
 
Question 3 
A 52 year old man who is suffering from chronic pelvic pain is diagnosed with increased pelvic 
floor tone.  Given that the patient’s prostatic bed was tender what non-pharmacological 
treatment is likely to make his symptoms worse? 
A Mindfulness 
B Discussion about how increased pelvic muscle floor tone can cause his symptoms 
C Cognitive behavioural therapy 
D Pelvic floor relaxation exercises 
E Pelvic floor strengthening exercises 
 
Correct answer: E. E is correct as this would worsen his symptoms. Tenderness of the prostatic bed 
can be an indication of increase pelvic muscle floor tone. Patients, even after a detailed explanation 
of the importance of pelvic floor muscle relaxation exercises, find these difficult to undertake and 
inadvertently focus on strengthening not relaxation after the initial consultation. It is important to 
explore this at the follow-up consultations if symptoms have not improved.  B in conjunction with D 
is likely to be helpful through making the patient aware of their pelvic floor and how to relax the 
muscles to improve symptoms. A can also aid with pelvic floor relaxation. C can be beneficial if 
increased pelvic floor tone is thought to be secondary to anxiety.  
 
 
